BioMarin Pharmaceutical Inc.
BMRN
$53.82
-$0.49-0.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.97% | 10.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.97% | 10.77% | |||
| Cost of Revenue | -55.01% | 0.36% | |||
| Gross Profit | 23.74% | 18.20% | |||
| SG&A Expenses | 15.56% | 12.69% | |||
| Depreciation & Amortization | 0.02% | -0.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.01% | 5.23% | |||
| Operating Income | -116.86% | 23.67% | |||
| Income Before Tax | -108.84% | 25.11% | |||
| Income Tax Expenses | -92.29% | 9.41% | |||
| Earnings from Continuing Operations | -112.78% | 29.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -112.78% | 29.54% | |||
| EBIT | -116.86% | 23.67% | |||
| EBITDA | -109.55% | 20.12% | |||
| EPS Basic | -112.77% | 28.91% | |||
| Normalized Basic EPS | -108.83% | 24.50% | |||
| EPS Diluted | -113.02% | 28.85% | |||
| Normalized Diluted EPS | -109.07% | 24.72% | |||
| Average Basic Shares Outstanding | 0.07% | 0.49% | |||
| Average Diluted Shares Outstanding | -2.57% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||